|
Toxicity results from a novel phase I/II trial of VMAT radiotherapy to prostate and pelvic nodes plus six cycles of radium-223 in mCSPC metastatic to bone post ADT and docetaxel. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Almac Diagnostics; Bayer; Janssen-Cilag; Movember Foundation |
Speakers' Bureau - Genzyme; Janssen-Cilag |
Travel, Accommodations, Expenses - Astellas Pharma; Janssen-Cilag |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |